- Home
- DEVS vs NLSP Comparison
DEVS vs NLSP Comparison
Compare DEVS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- NLSP
- Stock Information
- Founded
- DEVS N/A
- NLSP 2015
- Country
- DEVS Canada
- NLSP Switzerland
- Employees
- DEVS N/A
- NLSP N/A
- Industry
- DEVS
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- NLSP Health Care
- Exchange
- DEVS NYSE
- NLSP Nasdaq
- Market Cap
- DEVS 11.9M
- NLSP 12.4M
- IPO Year
- DEVS N/A
- NLSP 2021
- Fundamental
- Price
- DEVS $0.34
- NLSP $2.10
- Analyst Decision
- DEVS
- NLSP
- Analyst Count
- DEVS 0
- NLSP 0
- Target Price
- DEVS N/A
- NLSP N/A
- AVG Volume (30 Days)
- DEVS 524.3K
- NLSP 269.6K
- Earning Date
- DEVS 07-22-2025
- NLSP 07-22-2025
- Dividend Yield
- DEVS N/A
- NLSP N/A
- EPS Growth
- DEVS N/A
- NLSP N/A
- EPS
- DEVS N/A
- NLSP N/A
- Revenue
- DEVS $10,164.00
- NLSP N/A
- Revenue This Year
- DEVS N/A
- NLSP N/A
- Revenue Next Year
- DEVS N/A
- NLSP N/A
- P/E Ratio
- DEVS N/A
- NLSP N/A
- Revenue Growth
- DEVS N/A
- NLSP N/A
- 52 Week Low
- DEVS $0.18
- NLSP $1.30
- 52 Week High
- DEVS $3.00
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- NLSP 46.61
- Support Level
- DEVS N/A
- NLSP $2.20
- Resistance Level
- DEVS N/A
- NLSP $3.08
- Average True Range (ATR)
- DEVS 0.00
- NLSP 0.25
- MACD
- DEVS 0.00
- NLSP -0.06
- Stochastic Oscillator
- DEVS 0.00
- NLSP 8.40
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.